表紙
市場調査レポート

眼科治療薬の世界市場:2015年〜2019年

Global Ophthalmic Therapeutic Market 2015-2019

発行 TechNavio (Infiniti Research Ltd.) 商品コード 258439
出版日 ページ情報 英文 146 Pages
即納可能
価格
本日の銀行送金レート: 1USD=102.06円で換算しております。
Back to Top
眼科治療薬の世界市場:2015年〜2019年 Global Ophthalmic Therapeutic Market 2015-2019
出版日: 2015年07月22日 ページ情報: 英文 146 Pages
概要

世界の眼科治療薬市場は、2014年〜2019年のCAGRで、6.53%の成長が見込まれています。

当レポートでは、世界の眼科治療薬市場について調査分析し、市場規模と成長率、市場動向、市場促進要因・課題、市場機会について検証するほか、主要ベンダーなどについて、体系的な情報を提供しています。

第1章 エグゼクティブサマリー

第2章 略語リスト

第3章 調査範囲

  • 市場概要

第4章 市場調査手法

  • 市場調査プロセス
  • 調査手法

第5章 イントロダクション

第6章 疾患の概要

  • 緑内障
  • ドライアイ症候群
  • 糖尿病性網膜症
  • 網膜静脈閉塞 (RVO)
  • 加齢黄斑変性症 (AMD)
  • 黄斑浮腫
  • 眼疾患の経済的負担

第7章 パイプライン分析

  • パイプラインポートフォリオ:緑内障
  • パイプラインポートフォリオ:ドライアイ症候群
  • パイプラインポートフォリオ:糖尿病性網膜症
  • パイプラインポートフォリオ:AMD
  • パイプラインポートフォリオ:RVO

第8章 市場情勢

  • 市場概要
  • 市場規模と予測
  • ファイブフォース分析

第9章 市場区分:疾患タイプ別

第10章 市場区分:投与経路別

第11章 市場区分:分子タイプ別

第12章 市場区分:剤形別

第13章 地域区分

  • 地域別

第14章 購入基準

第15章 市場成長促進要因

第16章 成長促進要因とその影響

第17章 市場の課題

第18章 成長促進要因と課題の影響

第19章 市場の動向

第20章 動向とその影響

第21章 ベンダー情勢

  • 競合シナリオ
  • 市場シェア分析
  • その他・将来の有力ベンダー

第22章 主要ベンダー分析

  • Actavis
  • Bayer
  • F. Hoffmann-La Roche
  • Merck
  • Novartis
  • Pfizer
  • Regeneron Pharmaceuticals

第23章 関連レポート

図表

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: IRTNTR6492

About Ophthalmic Diseases

Ophthalmology is the science of eyes. It is the branch of medicine concerned with the treatment of eye-related diseases and eye defects. Some of the common eye disorders are glaucoma, retinal diseases, conjunctivitis, refractive errors, color blindness, and retinitis. Many of the eye diseases do not show symptoms at early stages. They will be painless with no defect in vision until the disease progresses to an advanced stage. Regular eye checkups must be done to detect the development of any disorder. Proper care and hygiene must be ensured to protect the eyes.

Technavio's analysts forecast the global ophthalmic therapeutic market to grow at a CAGR of 6.53% over the period 2014-2019.

Covered in this Report

The report covers the present scenario and the growth prospects of the global ophthalmic therapeutic market for the period 2015-2019. To calculate the market size, the report considers revenue generated from the sales of various branded therapies, OTC drugs, and generics along with the drugs used as off-label for the treatment of ophthalmic disorders such as:

  • Glaucoma
  • Dry eye syndrome
  • Retinal disorders such as diabetic retinopathy, macular edema, RVO, and AMD

Technavio's report, Global Ophthalmic Therapeutic Market 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, APAC, and EMEA; it also covers the landscape of global ophthalmic therapeutic market and its growth prospects in the coming years. The report includes a discussion of the key vendors operating in this market.

Key Regions

  • Americas
  • APAC
  • EMEA

Key Vendors

  • Actavis
  • Bayer
  • F. Hoffmann-La Roche
  • Merck
  • Novartis
  • Pfizer
  • Regeneron Pharmaceuticals

Other Prominent Vendors

  • Acadia Pharmaceuticals
  • AC Immune
  • Acorn Biomedical
  • Acucela
  • Advanced Cell Technology
  • Aerie Pharmaceuticals
  • Alcon
  • Alexion Pharmaceuticals
  • Alimera Sciences
  • Allergan
  • Ampio Pharmaceuticals
  • Antisense Therapeutics
  • Avalanche Biotechnologies
  • BCN Peptides
  • Boehringer Ingelheim
  • Bristol-Myers Squibb
  • Carl Zeiss Meditec
  • Eleven Biotherapeutics
  • Falcon Pharmaceuticals
  • Gilead Sciences
  • GlaxoSmithKline
  • Glycadia
  • Icon Bioscience
  • iCo Therapeutics
  • Inotek Pharmaceuticals
  • Intellect Neurosciences
  • Isis Pharmaceuticals
  • Kowa Group
  • Laboratorios Sophia
  • Lexicon Pharmaceuticals
  • Lpath
  • Neurotech Pharma
  • NicOx
  • Numoda Capital
  • OPKO Health
  • Ophthotech Corporation
  • Ohr Pharmaceutical
  • Otsuka Pharmaceutical
  • PanOptica
  • Parexel International
  • Promedior
  • pSivida
  • Quark Pharmaceuticals
  • R-Tech Ueno
  • Santen Pharmaceutical
  • Seikagaku
  • Senju Pharmaceutical
  • Shire
  • SIFI
  • Sirnaomics
  • StemCells
  • ThromboGenics
  • Valeant Pharmaceuticals

Market Driver

  • Increase in Prevalence of Eye Diseases
  • For a full, detailed list, view our report

Market Challenge

  • Lack of Awareness
  • For a full, detailed list, view our report

Market Trend

  • Strategic Alliances
  • For a full, detailed list, view our report

Key Questions Answered in this Report

  • What will the market size be in 2019 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
  • What are the market opportunities and threats faced by the key vendors?
  • What are the strengths and weaknesses of the key vendors?

Table of Contents

01. Executive Summary

02. List of Abbreviations

03. Scope of the Report

  • 03.1. Market Overview
  • 03.2. Product Offerings

04. Market Research Methodology

  • 04.1. Market Research Process
  • 04.2. Research Methodology

05. Introduction

06. Disease Overview

  • 06.1. Glaucoma
    • 06.1.1. Understanding the Disease
    • 06.1.2. Types of Glaucoma
    • 06.1.3. Etiology
    • 06.1.4. Signs and Symptoms
    • 06.1.5. Diagnosis
    • 06.1.6. Management
    • 06.1.7. Epidemiology
  • 06.2. Dry Eye Syndrome
    • 06.2.1. Understanding the Disease
    • 06.2.2. Types of Dry Eye Syndrome
    • 06.2.3. Causes of Dry Eye Syndrome
    • 06.2.4. Risk Factors of Dry Eye Syndrome
    • 06.2.5. Signs and Symptoms
    • 06.2.6. Diagnosis
    • 06.2.7. Management
  • 06.3. Diabetic Retinopathy
    • 06.3.1. Understanding the Disease
    • 06.3.2. Etiology
    • 06.3.3. Diagnosis
    • 06.3.4. Classification
    • 06.3.5. Epidemiology
    • 06.3.6. Management
  • 06.4. RVO
    • 06.4.1. Understanding the Disease
    • 06.4.2. Types of RVO
    • 06.4.3. Etiology
    • 06.4.4. Diagnosis
    • 06.4.5. Management
  • 06.5. AMD
    • 06.5.1. Understanding the Disease
    • 06.5.2. Stages of AMD
    • 06.5.3. Types of AMD
    • 06.5.4. Etiology
    • 06.5.5. Signs and Symptoms
    • 06.5.6. Diagnosis
    • 06.5.7. Management
  • 06.6. Macular Edema
    • 06.6.1. Understanding the Disease
    • 06.6.2. Etiology
    • 06.6.3. Diagnosis
    • 06.6.4. Management
  • 06.7. Economic Burden of Ophthalmic Diseases

07. Pipeline Analysis

  • 07.1. Pipeline Portfolio: Glaucoma
    • 07.1.1. Rhopressa
    • 07.1.2. Roclatan
    • 07.1.3. Trabodenoson
    • 07.1.4. Lomerizine HCl
    • 07.1.5. Y-39983
  • 07.2. Pipeline Portfolio: Dry Eye Syndrome
    • 07.2.1. Lifitegrast
    • 07.2.2. OPC-12759E
    • 07.2.3. EBI-005
  • 07.3. Pipeline Portfolio: Diabetic Retinopathy
    • 07.3.1. Squalamine
    • 07.3.2. K-115-R/Ripasudil Hydrochloride Hydrate
  • 07.4. Pipeline Portfolio: AMD
    • 07.4.1. Anecortave Acetate (Suspension)
    • 07.4.2. E10030
    • 07.4.3. Abicipar
  • 07.5. Pipeline Portfolio: RVO
    • 07.5.1. TLC399
    • 07.5.2. AGN208397

08. Market Landscape

  • 08.1. Market Overview
  • 08.2. Market Size and Forecast
  • 08.3. Five Forces Analysis

09. Market Segmentation by Disease Type

  • 09.1. Global Ophthalmic Therapeutics Market by Disease Type
  • 09.2. Glaucoma
  • 09.3. Dry Eye Syndrome
  • 09.4. Retinal Disorders
    • 09.4.1. Diabetic Retinopathy
    • 09.4.2. Macular Edema
    • 09.4.3. AMD
    • 09.4.4. RVO
  • 09.5. Global Glaucoma Therapeutics Market
    • 09.5.1. Market Size and Forecast
  • 09.6. Global AMD Therapeutics Market
    • 09.6.1. Market Size and Forecast
  • 09.7. Global Macular Edema Therapeutics Market
    • 09.7.1. Market Size and Forecast
  • 09.8. Global Dry Eye Syndrome Therapeutics Market
    • 09.8.1. Market Size and Forecast
  • 09.9. Global Diabetic Retinopathy Therapeutics Market
    • 09.9.1. Market Size and Forecast
  • 09.10. Global RVO Therapeutics Market
    • 09.10.1. Market Size and Forecast

10. Market Segmentation by Route of Administration

  • 10.1. Topical
  • 10.2. Systemic
    • 10.2.1. IV
    • 10.2.2. Oral
  • 10.3. Intravitreal

11. Market Segmentation by Molecule Type

  • 11.1. Biologics
  • 11.2. Small Molecules

12. Market Segmentation by Dosage Form

  • 12.1. Solutions
  • 12.2. Implants
  • 12.3. Pills

13. Geographical Segmentation

  • 13.1. Global Ophthalmic Therapeutics Market by Geography 2014-2019

14. Buying Criteria

15. Market Growth Drivers

16. Drivers and Their Impact

17. Market Challenges

18. Impact of Drivers and Challenges

19. Market Trends

20. Trends and Their Impact

21. Vendor Landscape

  • 21.1. Competitive Scenario
    • 21.1.1. Key News
    • 21.1.2. Mergers and Acquisitions
  • 21.2. Market Share Analysis 2014
    • 21.2.1. Novartis
    • 21.2.2. Actavis
    • 21.2.3. F. Hoffmann-La Roche
    • 21.2.4. Regeneron Pharmaceuticals
    • 21.2.5. Bayer
    • 21.2.6. Pfizer
    • 21.2.7. Merck
  • 21.3. Other and Future Prominent Vendors

22. Key Vendor Analysis

  • 22.1. Actavis
    • 22.1.1. Key Facts
    • 22.1.2. Business Description
    • 22.1.3. Business Segmentation
    • 22.1.4. Business Segmentation by Revenue 2012 and 2013
    • 22.1.5. Sales by Geography
    • 22.1.6. Business Strategy
    • 22.1.7. Key Information
    • 22.1.8. SWOT Analysis
  • 22.2. Bayer
    • 22.2.1. Key Facts
    • 22.2.2. Business Overview
    • 22.2.3. Business Segmentation by Revenue 2014
    • 22.2.4. Business Segmentation by Revenue 2013 and 2014
    • 22.2.5. Geographical Segmentation by Revenue 2014
    • 22.2.6. Business Strategy
    • 22.2.7. Recent Developments
    • 22.2.8. SWOT Analysis
  • 22.3. F. Hoffmann-La Roche
    • 22.3.1. Key Facts
    • 22.3.2. Business Overview
    • 22.3.3. Business Segmentation
    • 22.3.4. Business Segmentation by Revenue 2012 and 2013
    • 22.3.5. Sales by Geography
    • 22.3.6. Business Strategy
    • 22.3.7. Key Information
    • 22.3.8. SWOT Analysis
  • 22.4. Merck
    • 22.4.1. Key Facts
    • 22.4.2. Business Overview
    • 22.4.3. Business Segmentation by Revenue 2013
    • 22.4.4. Business Segmentation by Revenue 2012 and 2013
    • 22.4.5. Sales by Geography
    • 22.4.6. Business Strategy
    • 22.4.7. Key Developments
    • 22.4.8. SWOT Analysis
  • 22.5. Novartis
    • 22.5.1. Key Facts
    • 22.5.2. Business Description
    • 22.5.3. Business Segmentation
    • 22.5.4. Revenue by Business Segmentation
    • 22.5.5. Revenue Comparison 2012 and 2013
    • 22.5.6. Sales by Geography
    • 22.5.7. Business Strategy
    • 22.5.8. Key Developments
    • 22.5.9. SWOT Analysis
  • 22.6. Pfizer
    • 22.6.1. Key Facts
    • 22.6.2. Business Overview
    • 22.6.3. Business Segmentation by Revenue 2014
    • 22.6.4. Business Segmentation by Revenue 2013 and 2014
    • 22.6.5. Geographical Segmentation by Revenue 2014
    • 22.6.6. Business Strategy
    • 22.6.7. Key developments
    • 22.6.8. SWOT Analysis
  • 22.7. Regeneron Pharmaceuticals
    • 22.7.1. Key Facts
    • 22.7.2. Business Overview
    • 22.7.3. Product Segmentation
    • 22.7.4. Revenue Product Segmentation
    • 22.7.5. Business Strategy
    • 22.7.6. Key Information
    • 22.7.7. SWOT Analysis

23. Other Reports in This Series

List of Exhibits

  • Exhibit 1: Market Research Methodology
  • Exhibit 2: Major Ophthalmic Conditions
  • Exhibit 3: Types of Glaucoma
  • Exhibit 4: Development of Diabetic Retinopathy
  • Exhibit 5: Classification of Diabetic Retinopathy
  • Exhibit 6: Types of RVO
  • Exhibit 7: Types of AMD
  • Exhibit 8: Global Ophthalmic Therapeutics Market 2014-2019 ($ millions)
  • Exhibit 9: Global Ophthalmic Therapeutics Market by Disease Type
  • Exhibit 10: Global Ophthalmic Therapeutics Market by Disease Type 2014
  • Exhibit 11: Global Glaucoma Therapeutics Market 2014-2019 ($ millions)
  • Exhibit 12: Key Takeaways: Global Glaucoma Therapeutics Market
  • Exhibit 13: Global AMD Therapeutics Market 2014-2019 ($ millions)
  • Exhibit 14: Key Takeaways: Global AMD Therapeutics Market
  • Exhibit 15: Global Macular Edema Therapeutics Market 2014-2019 ($ millions)
  • Exhibit 16: Key Takeaways: Global Macular Edema Therapeutics Market
  • Exhibit 17: Global Dry Eye Syndrome Therapeutics Market 2014-2019 ($ millions)
  • Exhibit 18: Key Takeaways: Global Dry Eye Syndrome Therapeutics Market
  • Exhibit 19: Global Diabetic Retinopathy Therapeutics Market 2014-2019 ($ millions)
  • Exhibit 20: Key Takeaways: Global Diabetic Retinopathy Therapeutics Market
  • Exhibit 21: Global RVO Therapeutics Market 2014-2019 ($ millions)
  • Exhibit 22: Key Takeaways: Global RVO Therapeutics Market
  • Exhibit 23: Global Ophthalmic Therapeutics Market: YoY Growth Rate and Revenue by Disease Type 2014-2019
  • Exhibit 24: Global Ophthalmic Therapeutics Market by Route of Administration
  • Exhibit 25: Global Ophthalmic Therapeutics Market by Molecule Type
  • Exhibit 26: Global Ophthalmic Therapeutics Market by Dosage Form
  • Exhibit 27: Global Ophthalmic Therapeutics Market by Geography 2014
  • Exhibit 28: Major Drivers of Global Ophthalmic Therapeutics Market
  • Exhibit 29: Major Challenges in Global Ophthalmic Therapeutics Market
  • Exhibit 30: Major Trends in Global Ophthalmic Therapeutics Market
  • Exhibit 31: Vendor Ranking 2014
  • Exhibit 32: Novartis: YoY Revenue and Growth Rate of Lucentis 2011-2014 ($ millions)
  • Exhibit 33: Actavis: YoY Revenue of Restasis 2012-2014 ($ millions)
  • Exhibit 34: Actavis: YoY Revenue of Lumigan 2012-2014 ($ millions)
  • Exhibit 35: Actavis: YoY Revenue of Alphagan, Alphagan P, and Combigan 2012-2014 ($ millions)
  • Exhibit 36: F. Hoffmann-La Roche: YoY Revenue and Growth Rate of Lucentis 2011-2014 ($ millions)
  • Exhibit 37: Regeneron Pharmaceuticals: YoY Revenue and Growth Rate of Eylea 2011-2014 ($ millions)
  • Exhibit 38: Bayer: YoY Revenue and Growth Rate of Eylea 2012-2014 ($ millions)
  • Exhibit 39: Pfizer: YoY Revenue and Growth Rate of Xalatan/Xalacom 2012-2014 ($ millions)
  • Exhibit 40: Actavis: Business Segmentation 2013
  • Exhibit 41: Actavis: Business Segmentation by Revenue 2012 and 2013 ($ millions)
  • Exhibit 42: Actavis: Sales by Geography ($ millions)
  • Exhibit 43: Bayer: Business Segmentation by Revenue 2014
  • Exhibit 44: Bayer: Business Segmentation by Revenue 2013 and 2014 ($ billions)
  • Exhibit 45: Bayer: Geographical Segmentation by Revenue 2014
  • Exhibit 46: Business Segmentation of F. Hoffmann-La Roche 2013
  • Exhibit 47: F. Hoffmann-La Roche: Business Segmentation by Revenue 2012 and 2013
  • Exhibit 48: F. Hoffmann-La Roche: Sales by Geography 2013 (Pharmaceuticals Division)
  • Exhibit 49: F. Hoffmann-La Roche: Sales by Geography 2013 (Diagnostics Division)
  • Exhibit 50: Merck: Business Segmentation by Revenue 2013
  • Exhibit 51: Merck: Business Segmentation by Revenue 2012 and 2013 ($ billions)
  • Exhibit 52: Merck: Sales by Geography 2013
  • Exhibit 53: Novartis: Business Segmentation
  • Exhibit 54: Novartis: Revenue by Business Segmentation 2013
  • Exhibit 55: Novartis AG: Revenue by Business Segmentation 2012 and 2013 ($ millions)
  • Exhibit 56: Novartis: Revenue by Geographical Segmentation 2013
  • Exhibit 57: Pfizer: Business Segmentation by Revenue 2014
  • Exhibit 58: Pfizer: Business Segmentation by Revenue 2013 and 2014 ($ billions)
  • Exhibit 59: Pfizer: Geographical Segmentation by Revenue 2014
  • Exhibit 60: Regeneron Pharmaceuticals: Product Segmentation
  • Exhibit 61: Regeneron Pharmaceuticals: Revenue Product Segmentation 2013
Back to Top